Related Experiment Video

Updated: Jun 24, 2026

Development of an In Vitro Assay to Evaluate Contractile Function of Mesenchymal Cells that Underwent Epithelial-Mesenchymal Transition
06:02

Development of an In Vitro Assay to Evaluate Contractile Function of Mesenchymal Cells that Underwent Epithelial-Mesenchymal Transition

Published on: June 10, 2016

Transforming growth factor-beta and angiotensin in fibrosis and burn injuries

Vincent Ashley Gabriel1

  • 1Department of Physical Medicine and Rehabilitation, University of Texas Southwestern Medical Center, Dallas, Texas 75390-9055, USA.

Journal of Burn Care & Research : Official Publication of the American Burn Association
|April 8, 2009
PubMed

Insights

Transforming growth factor-beta (TGF-beta) and angiotensin II (AT II) activate Smad proteins, promoting fibrosis. This pathway is crucial in burn scarring and other fibrotic conditions, offering new research and treatment avenues.

Area of Science:

  • Biomedical research
  • Cellular signaling pathways
  • Fibrosis mechanisms

Background:

  • Fibrosis, characterized by excessive extracellular matrix deposition, underlies various human diseases.
  • Transforming growth factor-beta (TGF-beta) is a key mediator in fibrotic processes.
  • Angiotensin II (AT II) has been implicated in fibrotic conditions.

Purpose of the Study:

  • To review the roles of TGF-beta, Smad proteins, and AT II in human fibrosis.
  • To highlight the potential synergistic role of AT II with TGF-beta in burn scarring.
  • To update researchers and practitioners on this signaling pathway.

Main Methods:

  • Literature search of MEDLINE database for relevant English manuscripts.
  • Keywords included: TGF-beta, Smad, angiotensin, fibrosis, burn, scar.
  • Review and synthesis of existing research on the topic.

Main Results:

  • Both AT II and TGF-beta activate the Smad protein signaling pathway.
  • This activation leads to the overexpression of genes associated with fibrosis.
  • AT II acts independently and synergistically with TGF-beta in fibrotic conditions like nephritis, sclerosis, and myocardial infarction.

Conclusions:

  • The AT II and TGF-beta interaction via Smad proteins is a significant driver of fibrosis in various human diseases.
  • This pathway is potentially important in the pathogenesis of human burn scarring.
  • Understanding this interaction may lead to novel therapeutic strategies for fibrotic diseases, including burns.

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Introduction to Fibroblasts01:09

Introduction to Fibroblasts

Rudolph Virchow discovered spindle-shaped cells called fibroblasts in 1858. Inactive fibroblasts, called fibrocytes, become activated by various stimuli, such as growth factors and inflammatory cytokines. Activated fibroblasts play a crucial role in wound healing, inflammation, formation of new blood vessels, and cancer progression. Uncontrolled activation of fibroblasts results in fibrosis, the excess deposition of fibrous tissue, which can lead to scarring and affect normal organs. This...
Healing I: Introduction01:11

Healing I: Introduction

Healing is the physiological process by which the body restores the integrity and function of damaged tissues following injury. It involves a coordinated interplay of cellular proliferation, extracellular matrix remodeling, and growth factor signaling. The extent and nature of the tissue damage determine whether healing occurs by resolution, regeneration, or replacement.ResolutionResolution represents the most complete form of healing, occurring when the injury is minimal and tissue...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...